Colorectal Cancer Forecast and Market Analysis to 2036

  • ID: 3797434
  • Report
  • 650 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Colorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiator between colon cancer and rectal cancer is the location of the primary tumor, but identical etiology and similar risk factors and symptoms mean that they are often grouped together. CRC is believed to arise as a result of interactions between inherited and environmental factors. Despite improved prognosis of CRC patients in the last decade following advances in treatment options, survival rates still lag behind those of breast and prostate cancer patients.

Market Snapshot
  • Avastin will remain the leading targeted therapy in the colorectal cancer market through to 2024.
  • Avastin in combination with FOLFOX remains the most commonly prescribed first-line treatment for Stage IV disease.
  • As screening has not yet affected incidence rates, incident cases are predicted to increase between 2016 and 2036.
  • Approved drugs seek label expansions to better compete as patent expiries threaten to erode branded sales of Avastin and Erbitux.
  • Pipeline candidates will pursue novel mechanisms of action to distinguish themselves in an increasingly crowded market.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: COLORECTAL CANCER IN THE US, JAPAN, AND 5EU (Published on 11 December 2017)
EXECUTIVE SUMMARY
RECENT FORECAST UPDATES
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
BIBLIOGRAPHY
PRODUCT PROFILE: AVASTIN
PRODUCT PROFILE (LATE STAGE): COTELLIC
PRODUCT PROFILE: CYRAMZA
PRODUCT PROFILE: ERBITUX
PRODUCT PROFILE: KEYTRUDA
PRODUCT PROFILE: LONSURF
PRODUCT PROFILE (LATE STAGE): ONCOVAX
PRODUCT PROFILE: OPDIVO
PRODUCT PROFILE: STIVARGA
PRODUCT PROFILE: TS-1
PRODUCT PROFILE (LATE STAGE): TECENTRIQ
PRODUCT PROFILE: VECTIBIX
PRODUCT PROFILE: ZALTRAP
PRODUCT PROFILE (LATE STAGE): BINIMETINIB
PRODUCT PROFILE (LATE STAGE): LEFITOLIMOD
PRODUCT PROFILE (LATE STAGE): MASITINIB
PRODUCT PROFILE (LATE STAGE): NAPABUCASIN

TREATMENT: COLORECTAL CANCER IN THE US, JAPAN, AND 5EU (Published on 25 August 2017)
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS

EPIDEMIOLOGY: COLORECTAL CANCER IN THE US, JAPAN, AND 5EU (Published on 31 July 2017)
EXECUTIVE SUMMARY
DISEASE BACKGROUND
SOURCES AND METHODOLOGY
FORECAST
EPIDEMIOLOGIST INSIGHT
STRENGTHS AND LIMITATIONS
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: COLORECTAL CANCER (Published on 11 December 2017)
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
PRODUCT PROFILE: AVASTIN
PRODUCT PROFILE: CYRAMZA
PRODUCT PROFILE: ERBITUX
PRODUCT PROFILE: KEYTRUDA
PRODUCT PROFILE: LONSURF
PRODUCT PROFILE: OPDIVO
PRODUCT PROFILE: STIVARGA
PRODUCT PROFILE: TS-1
PRODUCT PROFILE: VECTIBIX
PRODUCT PROFILE: ZALTRAP
PIPELINE: COLORECTAL CANCER (Published on 11 December 2017)
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
PRODUCT PROFILE (LATE STAGE): COTELLIC
PRODUCT PROFILE (LATE STAGE): ONCOVAX
PRODUCT PROFILE (LATE STAGE): TECENTRIQ
PRODUCT PROFILE (LATE STAGE): BINIMETINIB
PRODUCT PROFILE (LATE STAGE): ENCORAFENIB
PRODUCT PROFILE (LATE STAGE): LEFITOLIMOD
PRODUCT PROFILE (LATE STAGE): MASITINIB
PRODUCT PROFILE (LATE STAGE): NAPABUCASIN
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll